Bone Marrow Stem Cells

Archive for the ‘Bone Marrow Stem Cells’ Category

Experimental Neurology Journal: BrainStorm's NurOwn™ Stem Cell Technology Shows Promise for Treating Huntington's …

February 2nd, 2012

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI.OB - News), a leading developer of adult stem cell technologies and therapeutics, announced today that the prestigious Experimental Neurology Journal, published an article indicating that preclinical studies using cells that underwent treatment with Brainstorm’s NurOwn™ technology show promise in an animal model of Huntington’s disease. The article was published by leading scientists including Professor Melamed and Professor Offen of the Tel Aviv University.

In these studies, bone marrow derived mesenchymal stem cells secreting neurotrophic factors (MSC-NTF), from patients with Huntington’s disease, were transplanted into the animal model of this disease and showed therapeutic improvement.

“The findings from this study demonstrate that stem cells derived from patients with a neurodegenerative disease, which are processed using BrainStorm’s NurOwn™ technology, may alleviate neurotoxic signs, in a similar way to cells derived from healthy donors. This is an important development for the company, as it confirms that autologous transplantation may be beneficial for such additional therapeutic indications,” said Dr. Adrian Harel, BrainStorm’s CEO.

"These findings provide support once again that BrainStorm’s MSC-NTF secreting cells have the potential to become a platform that in the future will provide treatment for various neuro-degenerative diseases," says Chaim Lebovits, President of BrainStorm. "This study follows previously published pre-clinical studies that demonstrated improvement in animal models of neurodegenerative diseases such as Parkinson’s, Multiple Sclerosis (MS) and neural damage such as optic nerve transection and sciatic nerve injury. Therefore, BrainStorm will consider focusing on a new indication in the near future, in addition to the ongoing Clinical Trials in ALS.”

BrainStrom is currently conducting a Phase I/II Human Clinical Trial for Amyotrophic Lateral Sclerosis (ALS) also known as Lou Gehrig’s disease at the Hadassah Medical center. Initial results from the clinical trial (which is designed mainly to test the safety of the treatment), that were announced last week, have shown that the Brainstorm’s NurOwn™ therapy is safe and does not show any significant treatment-related adverse events and have also shown certain signs of beneficial clinical effects.

To read the Article entitled ‘Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: A potential therapy for Huntington's disease’ by Sadan et al. please go to:

http://www.sciencedirect.com/science/article/pii/S0014488612000295

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotech company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The company, through its wholly owned subsidiary Brainstorm Cell Therapeutics Ltd., holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The technology is currently in a Phase I/II clinical trials for ALS in Israel.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements, including, inter alia, regarding safety and efficacy in its human clinical trials and thereafter; the Company's ability to progress any product candidates in pre-clinical or clinical trials; the scope, rate and progress of its pre-clinical trials and other research and development activities; the scope, rate and progress of clinical trials we commence; clinical trial results; safety and efficacy of the product even if the data from pre-clinical or clinical trials is positive; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of our proposed product candidates; dependence on the efforts of third parties; failure by us to secure and maintain relationships with collaborators; dependence on intellectual property; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility, and risks that we may lack the financial resources and access to capital to fund our operations. The potential risks and uncertainties include risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect its technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. The Company does not undertake any obligation to update forward-looking statements made by us.

Read the original post:
Experimental Neurology Journal: BrainStorm's NurOwn™ Stem Cell Technology Shows Promise for Treating Huntington's ...

Comments Closed|

Stem cell therapy shows promise for stroke

February 2nd, 2012

By Maureen Salamon
HealthDay Reporter

WEDNESDAY, Feb. 1 (HealthDay News) -- Treating stroke patients with stem cells taken from their own bone marrow appears to safely help them regain some of their lost abilities, two small new studies suggest.

Indian researchers observed mixed results in the extent of stroke patients' improvements, with one study showing marked gains in daily activities, such as feeding, dressing and movement, and the other study noting these improvements to be statistically insignificant. But patients seemed to safely tolerate the treatments in both experiments with no ill effects, study authors said.

"The results are encouraging to know but we need a larger, randomized study for more definitive conclusions," said Dr. Rohit Bhatia, a professor of neurology at the All India Institute of Medical Sciences in New Delhi, and author of one of the studies. "Many questions -- like timing of transplantation, type of cells, mode of transplantation, dosage [and] long-term safety -- need answers before it can be taken from bench to bedside."

The studies are scheduled to be presented Wednesday and Thursday at the American Stroke Association's annual meeting in New Orleans.

Stem cells -- unspecialized cells from bone marrow, umbilical cord blood or human embryos that can change into cells with specific functions -- have been explored as potential therapies for a host of diseases and conditions, including cancer and strokes.

In one of the current studies, 120 moderately affected stroke patients ranging from 18 to 75 years old were split into two groups, with half infused intravenously with stem cells harvested from their hip bones and half serving as controls. About 73 percent of the stem cell group achieved "assisted independence" after six months, compared with 61 percent of the control group, but the difference wasn't considered statistically significant.

In the other study, presented by Bhatia, 40 patients whose stroke occurred between three and 12 months prior were also split into two groups, with half receiving stem cells, which were dissolved in saline and infused over several hours. When compared to controls, stroke patients receiving stem cell therapy showed statistically significant improvements in feeding, dressing and mobility, according to the study. On functional MRI scans, the stem cell recipients also demonstrated an increase in brain activity in regions that control movement planning and motor function.

Neither study yielded adverse effects on patients, which could include tumor development.

But Dr. Matthew Fink, chief of the division of stroke and critical care neurology at New York-Presbyterian Hospital/Weill Cornell Medical Center, said that the therapy's safety is the only thing the two studies seemed to demonstrate.

"The thing to keep in mind is that these are really phase one trials," said Fink, also a professor of neurology at Weill Cornell Medical College. "I'm concerned that people get the idea that now stem cell treatment is available for stroke, and that's not the case."

Fink noted that the cells taken from study participants' hip bones can only be characterized as "bone marrow aspirates" since the authors didn't prove that actual stem cells were extracted.

"They haven't really analyzed if they're stem cells and what they turn into when they go into circulation," he added. "The best way to look at this is, it's very preliminary . . . when patients come to me to talk about it, I'm going to tell them it's years away before we know if this is going to work."

Studies presented at scientific conferences should be considered preliminary until published in a peer-reviewed medical journal.

More information

The U.S. National Institutes of Health has more information on stem cells.

Continued here:
Stem cell therapy shows promise for stroke

Comments Closed|

Police officers offer bone marrow

February 2nd, 2012

2 February 2012 Last updated at 08:31 ET

More than 100 police officers in Cornwall have signed up to become bone marrow donors.

Insp Dave Meredith, of Devon and Cornwall Police, had appealed to staff to register for the medical procedure.

So far, 110 officers in Cornwall have signed up to the register in three weeks, with a call to Devon officers due to follow.

Insp Meridith said: "I'm very impressed but I think this reflects on the goodwill of the officers and staff."

'Saving someone's life'

Insp Meredith said he decided to encourage registration after the donation method changed.

Continue reading the main story “Start Quote

The bigger the pool, the bigger the chance”

End Quote Karen Archer Anthony Nolan charity

Donors register by providing a sample of saliva, and then 80% of those asked to donate, do so by giving blood, from which their stem cells are retrieved.

Insp Meredith said: "In light of those changes I thought I've really got to take one step forward.

"People were a little apprehensive at first but once they thought about it and realised the implication and that they were potentially saving someone's life they readily agreed."

Simon Wilcock, an officer in Newquay who had Hodgkin's Lymphoma ten years ago, said: "I was on chemotherapy at the time and it had worked to a point.

"But it had got to the stage where without a transplant there's no doubt that in a few months I probably wouldn't have survived."

The appeal to the force was issued three weeks ago with the volunteers required to be aged between 18 and 40, although those on the register remain on it until they turn 60.

Karen Archer from the charity, Anthony Nolan, said: "It takes one person to save a life so if we've got 110 people joining the register then that's amazing news.

"People can be waiting years for that one right person to join the register, but there are 1000s of people waiting at any one time.

"The bigger the pool, the bigger the chance."

Read the original here:
Police officers offer bone marrow

Comments Closed|

Cardiovascular Drug Delivery – technologies,markets and companies

February 1st, 2012

NEW YORK, Feb. 1, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Cardiovascular Drug Delivery - technologies,markets and companies

http://www.reportlinker.com/p0203538/Cardiovascular-Drug-Delivery---technologiesmarkets-and-companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

Drug delivery to the cardiovascular system is different from delivery to other systems because of the anatomy and physiology of the vascular system; it supplies blood and nutrients to all organs of the body. Drugs can be introduced into the vascular system for systemic effects or targeted to an organ via the regional blood supply. In addition to the usual formulations of drugs such as controlled release, devices are used as well. This report starts with an introduction to molecular cardiology and discusses its relationship to biotechnology and drug delivery systems.

Drug delivery to the cardiovascular system is approached at three levels: (1) routes of drug delivery; (2) formulations; and finally (3) applications to various diseases. Formulations for drug delivery to the cardiovascular system range from controlled release preparations to delivery of proteins and peptides. Cell and gene therapies, including antisense and RNA interference, are described in full chapters as they are the most innovative methods of delivery of therapeutics. Various methods of improving systemic administration of drugs for cardiovascular disorders are described including use of nanotechnology.

Cell-selective targeted drug delivery has emerged as one of the most significant areas of biomedical engineering research, to optimize the therapeutic efficacy of a drug by strictly localizing its pharmacological activity to a pathophysiologically relevant tissue system. These concepts have been applied to targeted drug delivery to the cardiovascular system. Devices for drug delivery to the cardiovascular system are also described.

Role of drug delivery in various cardiovascular disorders such as myocardial ischemia, hypertension and hypercholesterolemia is discussed. Cardioprotection is also discussed. Some of the preparations and technologies are also applicable to peripheral arterial diseases. Controlled release systems are based on chronopharmacology, which deals with the effects of circadian biological rhythms on drug actions.A full chapter is devoted to drug-eluting stents as treatment for restenosis following stenting of coronary arteries.Fifteen companies are involved in drug-eluting stents.

New cell-based therapeutic strategies are being developed in response to the shortcomings of available treatments for heart disease. Potential repair by cell grafting or mobilizing endogenous cells holds particular attraction in heart disease, where the meager capacity for cardiomyocyte proliferation likely contributes to the irreversibility of heart failure. Cell therapy approaches include attempts to reinitiate cardiomyocyte proliferation in the adult, conversion of fibroblasts to contractile myocytes, conversion of bone marrow stem cells into cardiomyocytes, and transplantation of myocytes or other cells into injured myocardium.

Advances in molecular pathophysiology of cardiovascular diseases have brought gene therapy within the realm of possibility as a novel approach to treatment of these diseases. It is hoped that gene therapy will be less expensive and affordable because the techniques involved are simpler than those involved in cardiac bypass surgery, heart transplantation and stent implantation. Gene therapy would be a more physiologic approach to deliver vasoprotective molecules to the site of vascular lesion. Gene therapy is not only a sophisticated method of drug delivery; it may at time need drug delivery devices such as catheters for transfer of genes to various parts of the cardiovascular system.

The cardiovascular drug delivery markets are estimated for the years 2011 to 2021 on the basis of epidemiology and total markets for cardiovascular therapeutics. The estimates take into consideration the anticipated advances and availability of various technologies, particularly drug delivery devices in the future. Markets for drug-eluting stents are calculated separately. Role of drug delivery in developing cardiovascular markets is defined and unmet needs in cardiovascular drug delivery technologies are identified.

Selected 80 companies that either develop technologies for drug delivery to the cardiovascular system or products using these technologies are profiled and 74 collaborations between companies are tabulated. The bibliography includes 200 selected references from recent literature on this topic. The report is supplemented with 27 tables and 7 figures

TABLE OF CONTENTS

0. Executive Summary 11

1. Cardiovascular Diseases 13

Introduction 13

History of cardiovascular drug delivery 13

Overview of cardiovascular disease 14

Coronary artery disease 14

Angina pectoris 14

Limitations of current therapies for myocardial ischemic disease 14

Cardiomyopathies 14

Cardiac arrhythmias 15

Congestive heart failure 15

Peripheral arterial disease 15

Current management 16

Atherosclerosis 16

The endothelium as a target for cardiovascular therapeutics 16

Molecular cardiology 17

Cardiogenomics 17

Cardioproteomics 17

Personalized cardiology 18

Pharmacogenomics of cardiovascular disorders 18

Modifying the genetic risk for myocardial infarction 19

Management of heart failure 19

Management of hypertension 20

Pharmacogenomics of diuretic drugs 20

Pharmacogenomics of ACE inhibitors 20

Management of hypertension by personalized approach 21

Pharmacogenetics of lipid-lowering therapies 21

Polymorphisms in genes involved in cholesterol metabolism 21

Role of eNOS gene polymorphisms 22

Important advances in cardiovascular therapeutics 22

Drug delivery, biotechnology and the cardiovascular system 23

Role of cardiovascular imaging in cardiovascular therapeutics 23

Chronopharmacotherapy of cardiovascular diseases 23

2. Methods for Drug Delivery to the Cardiovascular System 25

Introduction 25

Routes of drug delivery to the cardiovascular system 25

Local administration of drugs to the cardiovascular system 25

Intramyocardial drug delivery 25

Drug delivery via coronary venous system 26

Intrapericardial drug delivery 26

Formulations for drug delivery to the cardiovascular system 27

Sustained and controlled release 27

Programming the release at a defined time 28

Dosage formulation of calcium channel blockers 28

Sustained and controlled release verapamil 28

Methods of administration of proteins and peptides 28

Delivery of peptides by subcutaneous injection 29

Depot formulations and implants 29

Poly(ethylene glycol) technology 29

Liposomes for cardiovascular drug delivery 30

Microencapsulation for protein delivery 30

Localized delivery of biomaterials for tissue engineering 30

Oral delivery of proteins and peptides 30

DDS to improve systemic delivery of cardiovascular drugs 32

Nanotechnology-based drug delivery 32

Controlled delivery of nanoparticles to injured vasculature 33

Nanoparticles for cardiovascular imaging and targeted drug delivery 34

Nanofiber-based scaffolds with drug-release properties 34

Targeted drug delivery to the cardiovascular system 35

Immunotargeting of liposomes to activated vascular endothelial cells 35

PEGylated biodegradable particles targeted to inflamed endothelium 36

Devices for cardiovascular drug delivery 36

Local drug delivery by catheters 37

Microneedle for periarterial injection 38

Nanotechnology-based devices for the cardiovascular system 39

Liposomal nanodevices for targeted cardiovascular drug delivery 39

Nanotechnology approach to the problem of "vulnerable plaque" 40

Drug delivery in the management of cardiovascular disease 40

Drug delivery in the management of hypertension 40

Transnasal drug delivery for hypertension 41

Transdermal drug delivery for hypertension 41

Oral extended and controlled release preparations for hypertension 42

Long-acting hypertensives for 24 h blood pressure control 43

Drug delivery to control early morning blood pressure peak 43

Role of drug delivery in improving compliance with antihypertensive therapy 44

Drug delivery for congestive heart failure 44

Oral human brain-type natriuretic peptide 44

Nitric oxide-based therapies for congestive heart failure 44

Automated drug delivery system for cardiac failure 45

DDS in the management of ischemic heart disease 45

Intravenous emulsified formulations of halogenated anesthetics 46

Injectable peptide nanofibers for myocardial ischemia 46

Delivery of angiogenesis-inducing agents for myocardial ischemia 47

Drug delivery for cardioprotection 47

Drug delivery for cardiac rhythm disorders 48

Drug delivery in the treatment of angina pectoris 49

Sustained and controlled-release nitrate for angina pectoris 49

Transdermal nitrate therapy 49

Controlled release calcium blockers for angina pectoris 51

Vaccines for hypertension 51

Drug delivery in the management of pulmonary hypertension 51

Prostacyclin by inhalation 52

Endothelin receptor antagonist treatment of PAH 52

Anticoagulation in cardiovascular disease 52

Oral heparin 52

Low molecular weight heparin-loaded polymeric nanoparticles 53

Transdermal anticoagulants 53

Thrombolysis for cardiovascular disorders 53

Use of ultrasound to facilitate thrombolysis 54

Delivery of alteplase through the AngioJet rheolytic catheter 54

Drug delivery for peripheral arterial disease 54

Delivery of thrombolytic agent to the clot through a catheter 55

Delivery of growth factors to promote angiogenesis in ischemic limbs 55

Immune modulation therapy for PAD 55

NO-based therapies for peripheral arterial disease 55

Drug delivery in the management of hypercholesterolemia 56

Controlled/sustained release formulations of statins 56

Combinations of statins with other drugs to increase efficacy 56

Controlled release fenofibrate 57

Extended release nicotinic acid 58

Intravenous infusion of lipoprotein preparations to raise HDL 59

Innovative approaches to hypercholesterolemia 59

Single dose therapy for more than one cardiovascular disorder 59

3. Cell Therapy for Cardiovascular Disorders 61

Introduction 61

Inducing the proliferation of cardiomyocytes 61

Role of stem cells in repair of the heart 61

Cell-mediated immune modulation for chronic heart disease 61

Cell therapy for atherosclerotic coronary artery disease 62

Transplantation of myoblasts for myocardial infarction 62

MyoCell™ (Bioheart) 63

Transplantation of cardiac progenitor cells for revascularization of myocardium 64

Methods of delivery of cells to the heart 64

Cellular cardiomyoplasty 64

IGF-1 delivery by nanofibers to improve cell therapy for MI 65

Intracoronary infusion of bone marrow-derived cells for AMI 65

Non-invasive delivery of cells to the heart by Morph®guide catheter 65

Transplantation of stem cells for myocardial infarction 66

Transplantation of embryonic stem cells 66

Transplantation of hematopoietic stem cells 66

Transplantation of cord blood stem cells for myocardial infarction 66

Intracoronary infusion of mobilized peripheral blood stem cells 67

Human mesenchymal stem cells for cardiac regeneration 67

Cytokine preconditioning of human fetal liver CD133+ SCs 68

Transplantation of expanded adult SCs derived from the heart 68

Transplantation of endothelial cells 68

Transplantation of genetically modified cells 69

Transplantation of cells secreting vascular endothelial growth factor 69

Transplantation of genetically modified bone marrow stem cells 69

Cell transplantation for congestive heart failure 69

Injection of adult stem cells for congestive heart failure 69

Intracoronary infusion of cardiac stem cells 70

Myoblasts for treatment of congestive heart failure 70

Role of cell therapy in cardiac arrhythmias 70

Atrioventricular conduction block 71

Ventricular tachycardia 71

ESCs for correction of congenital heart defects 72

Cardiac progenitors cells for treatment of heart disease in children 72

Stem cell therapy for peripheral arterial disease 73

Targeted delivery of endothelial progenitor cells labeled with nanoparticles 73

Clinical trials of cell therapy in cardiovascular disease 73

A critical evaluation of cell therapy for heart disease 75

Publications of clinical trials of cell therapy for CVD 76

Future directions for cell therapy of CVD 76

4. Gene Therapy for Cardiovascular Disorders 79

Introduction 79

Techniques of gene transfer to the cardiovascular system 80

Direct plasmid injection into the myocardium 80

Catheter-based systems for vector delivery 80

Ultrasound microbubbles for cardiovascular gene delivery 81

Vectors for cardiovascular gene therapy 81

Adenoviral vectors for cardiovascular diseases 81

Intravenous rAAV vectors for targeted delivery to the heart 82

Plasmid DNA-based delivery in cardiovascular disorders 82

Hypoxia-regulated gene therapy for myocardial ischemia 82

Angiogenesis and gene therapy of ischemic disorders 83

Therapeutic angiogenesis vs. vascular growth factor therapy 83

Gene painting for delivery of targeted gene therapy to the heart 84

Gene delivery to vascular endothelium 84

Targeted plasmid DNA delivery to the cardiovascular system with nanoparticles 84

Gene delivery by vascular stents 85

Gene therapy for genetic cardiovascular disorders 85

Genetic disorders predisposing to atherosclerosis 85

Familial hypercholesterolemia 86

Apolipoprotein E deficiency 87

Hypertension 87

Genetic factors for myocardial infarction 88

Acquired cardiovascular diseases 88

Coronary artery disease with angina pectoris 88

Ad5FGF-4 88

Ischemic heart disease with myocardial infarction 89

Angiogenesis for cardiovascular disease 89

Myocardial repair with IGF-1 therapy 90

miRNA gene therapy for ischemic heart disease 91

Congestive heart failure 91

Rationale of gene therapy in CHF 91

?-ARKct gene therapy 91

Intracoronary adenovirus-mediated gene therapy for CHF 92

AAV-mediated gene transfer for CHF 92

AngioCell gene therapy for CHF 93

nNOS gene transfer in CHF 93

Gene therapy for cardiac arrhythmias 93

Gene transfer for biological pacemakers 94

Management of arrhythmias due to myoblast transplantation 95

Genetically engineered cells as biological pacemakers 95

Gene therapy and heart transplantation 95

Gene therapy for peripheral arterial disease 96

Angiogenesis by gene therapy 96

HIF-1? gene therapy for peripheral arterial disease 96

HGF gene therapy for peripheral arterial disease 97

Ischemic neuropathy secondary to peripheral arterial disease 97

Maintaining vascular patency after surgery 97

Antisense therapy for cardiovascular disorders 98

Antisense therapy for hypertension 99

Antisense therapy for hypercholesterolemia 99

RNAi for cardiovascular disorders 100

RNAi for hypercholesterolemia 100

microRNA and the cardiovascular system 101

Role of miRNAs in angiogenesis 101

Role of miRNAs in cardiac hypertrophy and failure 101

Role of miRNAs in conduction and rhythm disorders of the heart 102

miRNA-based approach for reduction of hypercholesterolemia 102

miRNAs as therapeutic targets for cardiovascular diseases 103

Future prospects of miRNA in the cardiovascular therapeutics 103

Future prospects of gene therapy of cardiovascular disorders 103

Companies involved in gene therapy of cardiovascular disorders 104

5. Drug-Eluting Stents 107

Introduction 107

Percutaneous transluminal coronary angioplasty 107

Stents 107

Restenosis 107

Pathomechanism 108

Treatment 108

Nitric oxide-based therapies for restenosis 109

Carbon monoxide inhalation for preventing restenosis 109

Antisense approaches for prevention of restenosis after angioplasty 110

miRNA-based approach for restenosis following angioplasty 111

Gene therapy to prevent restenosis after angioplasty 111

Techniques of gene therapy for restenosis 112

NOS gene therapy for restenosis 113

Nonviral gene therapy to prevent intimal hyperplasia 113

HSV-1 gene therapy to prevent intimal hyperplasia 114

Drug delivery devices for restenosis 114

Local drug delivery by catheter 114

Stenosis associated with stents 115

Absorbable metal stents 115

Drug-eluting stents 115

Various types of DES 116

CYPHER® sirolimus-eluting coronary stent 116

Dexamethasone-eluting stents 116

NO-generating stents 117

Paclitaxel-eluting stents 117

Sirolimus-eluting vs paclitaxel-eluting stents 118

Novel technologies for DES 118

Absorbable DES 118

Bio-absorbable low-dose DES 119

Drug-eluting stents coated with polymer surfaces 119

Endeavour DES 119

Stents for delivery of gene therapy 120

Stem cell-based stents 121

VAN 10-4 DES 121

Nanotechnology-based stents 122

Drugs encapsulated in biodegradable nanoparticles 122

Magnetic nanoparticle-coated DES 122

Magnetic nanoparticles encapsulating paclitaxel targeted to stents 123

Nanocoated DES 123

Nanopores to enhance compatibility of DES 124

Paclitaxel-encapsulated targeted lipid-polymeric nanoparticles 124

The ideal DES 124

Companies developing drug-eluting stents 125

Clinical trials of drug-eluting stents 126

Measurements used in clinical trials of DES 126

TAXUS paclitaxel-eluting stents 126

XIENCE™ V everolimus-eluting coronary stent 127

COSTAR II clinical trial 128

Endeavor RESOLUTE zotarolimus-eluting stent system 128

CUSTOM I clinical trial 129

NOBORI CORE Trial 129

LEADERS trial 130

Comparison of DES in clinical trials 130

Comparison of DES with competing technologies 131

DES versus coronary artery bypass graft 131

DES versus bare metal stents 131

Multi-Link Vision bare metal stent vs DES 134

Guidelines for DES vs BMS 134

DES vs BMS for off-label indications 134

Role of DES in cases of bare-metal in-stent restenosis 135

DES versus balloon catheter coated with paclitaxel 135

DES versus intracoronary radiation therapy for recurrent stenosis 135

Cost-effectiveness of DES 136

Safety issues of DES 137

Adverse reactions to DES 137

Endothelial vascular dysfunction due to sirolismus 137

Risk of clotting with DES 137

Clopidogrel use and long-term outcomes of patients receiving DES 139

Prasugrel as antiplatelet agent 139

Effect of blood clot on release of drug from DES 140

Use of magnetized cell lining to prevent clotting of DES 140

Long-term safety studies of DES 140

Regulatory issues of DES 141

Future prospects for treatment of restenosis by DES 143

Future role of DES in management of cardiovascular diseases 143

Stent cost and marketing strategies 144

Improvements in stent technology 144

Bioabsorbale stent 144

DES vs drug-eluting balloons 145

6. Markets for Cardiovascular Drug Delivery 147

Introduction 147

Epidemiology of cardiovascular disease 147

Cost of care of cardiovascular disorders 148

Cardiovascular markets according to important diseases 149

Antithrombotics 149

Anticholesterol agents 149

Antihypertensive agents 150

Drugs for congestive heart failure 150

Markets for innovative technologies for cardiovascular disorders 150

Markets for cell therapy of cardiovascular disorders 150

Markets for gene therapy of cardiovascular disorders 151

Markets for drug-eluting stents 151

Major players in DES market 151

Impact of safety issues on future markets for DES 151

DES market in Asia 152

Patenting and legal issues of DES 153

The financial impact of DES on cardiovascular markets 153

Unmet needs for cardiovascular drug delivery 154

Role of DDS in developing cardiovascular markets 155

Markets for cardiovascular devices 155

Marketing of innovative cardiovascular drug delivery devices 155

Direct to consumer advertising of DES 156

Future trends in the integration of drug delivery with therapeutics 156

Future prospects of cardiovascular drug delivery 156

7. Companies involved in Cardiovascular Drug Delivery 157

Profiles of companies 157

Collaborations 243

8. References 247

List of Tables

Table 1 1: Landmarks in the historical evolution of cardiovascular drug delivery 13Table 1 2: Gene polymorphisms that alter cardiovascular response to drugs 18Table 2 1: Routes of drug delivery used for treatment of cardiovascular disorders 25Table 2 2: Formulations for drug delivery to the cardiovascular system 27Table 2 3: Improved methods of systemic drug delivery of cardiovascular drugs 32Table 2 4: Targeted delivery of therapeutic substances to the cardiovascular system 35Table 2 5: Classification of devices for drug delivery to the cardiovascular system 36Table 2 6: Various methods of delivery of therapeutic agents for hypertension 41Table 2 7: Marketed controlled/ extended release preparation for hypertension 43Table 2 8: Drug delivery in ischemic heart disease 45Table 2 9: Methods of delivery of nitrate therapy in angina pectoris 49Table 2 10: Drug delivery for peripheral arterial disorders 54Table 3 1: Clinical trials of cell therapy in cardiovascular disease 73Table 4 1: Cardiovascular disorders for which gene therapy is being considered. 79Table 4 2: Catheter-based systems for vector delivery to the cardiovascular system 80Table 4 3: Potential applications of antisense in cardiovascular disorders 99Table 4 4: Companies involved in gene therapy of cardiovascular diseases 104Table 5 1: Treatment of restenosis 108Table 5 2: Devices used for drug delivery in restenosis 114Table 5 3: Companies involved in drug-eluting stents 125Table 6 1: Prevalence of cardiovascular disorders in major markets: US 2011-2021 148Table 6 2: Prevalence of cardiovascular disorders in major markets: Europe 2011-2021 148Table 6 3: Prevalence of cardiovascular disorders in major markets: Japan 2011-2021 148Table 6 4: Values of cardiovascular DDS in major markets 2011-2021 149Table 6 5: Markets for innovative technologies for cardiovascular disorders 2011-2021 150Table 7 1: Top 5 companies in cardiovascular drug delivery 157Table 7 2: Collaborations in cardiovascular drug delivery 243

List of Figures

Figure 1 1: Drug delivery, biotechnology and cardiovascular diseases 23

Figure 2 1: MicroSyringe for periarterial injection 39

Figure 5 1: Vicious circle of vascular occlusion following angioplasty and stenting 109

Figure 5 2: Measurement of in-stent stenosis 115

Figure 5 3: Medtronic's Endeavour drug-eluting stent 120

Figure 5 4: Magnetic nanoparticle-coated stent 123

Figure 6 1: Unmet needs for cardiovascular drug delivery 154

To order this report:Drug Delivery Technology Industry: Cardiovascular Drug Delivery - technologies,markets and companies

More

Market Research Report

Check our

Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

Original post:
Cardiovascular Drug Delivery - technologies,markets and companies

Comments Closed|

Need muscle for a tough spot? Turn to fat stem cells, UC San Diego researchers say

January 31st, 2012

Public release date: 27-Jan-2012
[ | E-mail | Share ]

Contact: Daniel Kane
dbkane@ucsd.edu
858-534-3262
University of California - San Diego

Stem cells derived from fat have a surprising trick up their sleeves: Encouraged to develop on a stiff surface, they undergo a remarkable transformation toward becoming mature muscle cells. The new research appears in the journal Biomaterials. The new cells remain intact and fused together even when transferred to an extremely stiff, bone-like surface, which has University of California, San Diego bioengineering professor Adam Engler and colleagues intrigued. These cells, they suggest, could hint at new therapeutic possibilities for muscular dystrophy.

In diseases like muscular dystrophy or a heart attack, "muscle begins to die and undergoes its normal wounding processes," said Engler, a bioengineering professor at the Jacobs School of Engineering at UC San Diego. "This damaged tissue is fundamentally different from a mechanical perspective" than healthy tissue.

Transplanted stem cells might be able to replace and repair diseased muscle, but up to this point the transplants haven't been very successful in muscular dystrophy patients, he noted. The cells tend to clump into hard nodules as they struggle to adapt to their new environment of thickened and damaged tissue.

Engler, postdoctoral scholar Yu Suk Choi and the rest of the team think their fat-derived stem cells might have a better chance for this kind of therapy, since the cells seem to thrive on a stiff and unyielding surface that mimics the damaged tissue found in people with MD.

In their study in the journal Biomaterials, the researchers compared the development of bone marrow stem cells and fat-derived stem cells grown on surfaces of varying stiffness, ranging from the softness of brain tissue to the hardness of bone.

Cells from the fat lineage were 40 to 50 times better than their bone marrow counterparts at displaying the proper proteins involved in becoming muscle. These proteins are also more likely to "turn on" in the correct sequence in the fat-derived cells, Engler said.

Subtle differences in how these two types of cells interact with their environment are critical to their development, the scientists suggest. The fat-derived cells seem to sense their "niche" on the surfaces more completely and quickly than marrow-derived cells. "They are actively feeling their environment soon, which allows them to interpret the signals from the interaction of cell and environment that guide development," Choi explained.

Perhaps most surprisingly, muscle cells grown from the fat stem cells fused together, forming myotubes to a degree never previously observed. Myotubes are a critical step in muscle development, and it's a step forward that Engler and colleagues hadn't seen before in the lab.

The fused cells stayed fused when they were transferred to a very stiff surface. "These programmed cells are mature enough so that they don't respond the environmental cues" in the new environment that might cause them to split apart, Engler says.

Engler and colleagues will now test how these new fused cells perform in mice with a version of muscular dystrophy. The cells survive in an environment of stiff tissue, but Engler cautions that there are other aspects of diseased tissue such as its shape and chemical composition to consider. "From the perspective of translating this into a clinically viable therapy, we want to know what components of the environment provide the most important cues for these cells," he said.

###

Co-authors for the Biomaterials study "Mechanical derivation of functional myotubes from adipose-derived stem cells" include Ludovic G. Vincent and Andrew R. Lee in the Department of Bioengineering at the UC San Diego Jacobs School of Engineering, and Marek K. Dobke from the Division of Plastic Surgery, UC San Diego School of Medicine. The research was funded by the Human Frontier Science Program and the National Institutes of Health Common Fund.

[ | E-mail | Share ]

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Link:
Need muscle for a tough spot? Turn to fat stem cells, UC San Diego researchers say

Comments Closed|

ThermoGenesis Announces Management Transition in Conjunction With Tactical Realignment of Company

January 31st, 2012

RANCHO CORDOVA, Calif., Jan. 30, 2012 /PRNewswire/ -- ThermoGenesis Corp. (NASDAQ: KOOL - News), a leading supplier of innovative products and services that process and store adult stem cells, today announced that the Company has implemented a number of changes in corporate management responsibilities to maximize the Company's progress toward its strategic goals.

Matthew Plavan, currently Chief Financial Officer and Executive Vice President, Business Development, will become Chief Executive Officer and a member of the Board of Directors, while retaining his position as the Company's Chief Financial Officer. Plavan has served as Chief Financial Officer since 2005 and served as Chief Operating Officer from 2008-2010.

Plavan replaces J. Melville Engle, who has retired from his position as Chairman and Chief Executive Officer. Engle joined the Company as Chief Executive Officer in 2009 and was named Chairman of the Board in 2010. "ThermoGenesis has made important strides during Mel's tenure, as he was instrumental in building the ThermoGenesis management team and in the expansion of the Company's distributor network. We appreciate his contributions to the Company," said Patrick McEnany, a member of the board of directors.

"Given the uncertain duration of today's challenging global economy, we chose to reorganize the Company. The board believed changes were necessary if the Company was going to achieve its short-term objectives and be positioned for long-term growth. We believe Matt's experience, knowledge of our market and proven track record at ThermoGenesis makes him the most qualified person to lead the Company," McEnany added.

"I appreciate the board's confidence in me and believe our streamlined management is a strong and dedicated group of individuals that will drive the Company to success," Plavan stated. "Our current organization was staffed to support a faster entry of our products into new markets than we have achieved as of today, including China and India. The changes made today recalibrate the Company's resources to our current revenues and the cadence of new market opportunities, while maintaining the strong support our growing customer base has come to expect. We believe we are now optimally positioned to grow the business and maximize shareholder value, even in these turbulent economic times," Plavan added.

The Company indicated it has also eliminated eight additional positions. The Company will provide additional details on its new operating structure and objectives during its second quarter fiscal 2012 conference call on Thursday, February 9th.

The Company said it expects to record one-time expenses of approximately $500,000 related to the reorganization announced today in the third quarter of fiscal 2012. The restructured operations should result in an annualized expense reduction of approximately $2 million.

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These include:

The BioArchive® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant. AXP® AutoXpress® Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP® MarrowXpress® and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells, from bone marrow aspirates in the laboratory setting. The Res-Q® 60 BMC/PRP (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates and whole blood for platelet rich plasma (PRP). The CryoSeal® FS System, an automated device and companion sterile blood processing disposable, used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community.

This press release contains forward-looking statements. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA and foreign regulatory approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2012, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2012. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.
Web site: http://www.thermogenesis.com
Contact: Investor Relations
+1-916-858-5107, or
ir@thermogenesis.com

Link:
ThermoGenesis Announces Management Transition in Conjunction With Tactical Realignment of Company

Comments Closed|

Eastday-Leukemia boy gets op following cash appeal

January 30th, 2012

AN eight-year-old boy suffering from leukemia has undergone a
bone marrow transplant, after Shanghai Daily readers helped pay
for surgery.

Hundreds of readers who read about Xu Ping'an's plight in
November contributed to a fund that has raised more than
240,000 yuan (US$37,897).

The money is to help Xu Ping'an and his five-month-old brother,
Xu Pingkang, who has congenital heart disease.

The boys' father, Xu Xuebing, told Shanghai Daily yesterday
that his elder son was recovering well after the operation at a
local private hospital.

Doctors told him healthy blood stem cells given to Xu Ping'an
were still alive after 10 days, which is a positive sign.

"I am really grateful to the people who have helped us," said
Xu Xuebing.

He called on the government to help pay for further medical
treatment for his sons.

"I'm hoping the government can lend a hand to help my boys get
through this," said the father.

Xu Ping'an, originally from Jiangxi Province, was diagnosed
with leukemia in 2007. The family moved to Shanghai in the same
year to get better treatment for the boy.

Last year, Xu Xuebing and his wife, Zhang Yuehong, decided to
have a second child, after being told by doctors that a
transplant of their second child's umbilical cord blood stem
cells could save Xu Ping'an.

But when Xu Pingkang was born last September, he was found to
have congenital heart disease.

When the opportunity arose for an operation for the elder boy,
the family decided to use his mother's blood stem cells as the
baby was too weak to provide them for his brother.

Through donations, the family managed to pay for the first
phase of treatment but cannot afford total medical bills,
estimated at 350,000 yuan.

Xu Ping'an is receiving further treatment in the Shanghai
DaoPei Hospital and will remain there for at least a month,
according to his father.

More:
Eastday-Leukemia boy gets op following cash appeal

Comments Closed|